COMPANY UPDATES
02
May
2018
Novoheart to Debut New, State-of-the-art ‘Human Heart-in-a-Jar 2.0’ Technology at the 2018 International Society for Stem Cell Research (ISSCR) Annual Meeting

Novoheart announced that the next generation of its ‘Human heart-in-a-jar’ technology - which makes up a key component of its comprehensive MyHeartTM Platform - will be unveiled for the first time at the Annual Meeting of the International Society for Stem Cell Research (ISSCR), held in Melbourne, Australia from 20-23 June, 2018. The Annual Meeting is the flagship event of the professional society, where cutting-edge stem cell research will be presented to over 4,000 attendees which include notable scientists, innovators, industry representatives and media.

12
Apr
2018
Novoheart Founder & CEO Dr. Ronald Li honored with 2017 Distinguished Alumnus Award by the University of Waterloo

Novoheart is pleased to announce that Dr. Ronald Li, Founder and CEO of the Company, has been awarded with the 2017 Distinguished Alumnus Award by the University of Waterloo, Canada, from which he graduated with a B.Sc. in 1994. As one of two recipients of the award from the Faculty of Science, Dr. Li is recognized for his two decades of research on human cardiac tissue engineering, and his continuous efforts to translate and commercialize basic findings into tangible applications and community benefits, including the founding of Novoheart in 2014.

29
Mar
2018
Novoheart Files Patent Application on Disease Modeling Based on Landmark Research Conducted During Second Contract with Global Pharma Partner

Novoheart is pleased to announce that it has filed a patent application on the use of its proprietary MyHeartTM Platform of human bioengineered heart tissues to create disease models for neurological diseases in which afflicted patients suffer and often die from cardiac dysfunction. The IP, which is solely owned by Novoheart, was developed as part of the Company’s successfully completed second contract with a Global Pharma partner.

14
Mar
2018
Novoheart Opens New State-Of-The-Art Facilities at the Hong Kong Science Park

Novoheart is pleased to announce the opening of its brand new Hong Kong facility consisting of 5,300 ft² of integrated laboratory and office space. Located in the Hong Kong Science Park, the laboratory is equipped with state-of-the-art facilities for stem cell production, tissue engineering and world-class research and development. The facility provides Novoheart with a new level of scalability enabling it to accommodate a significant number of additional revenue-generating commercial contracts and projects.